P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression
نویسندگان
چکیده
منابع مشابه
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
BACKGROUND Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is clinically beneficial and attempted to identify clinicopathologic characteristics associated with patients who experience clinical benefit. PATIE...
متن کاملassessment of deep word knowledge in elementary and advanced iranian efl learners: a comparison of selective and productive wat tasks
testing plays a vital role in any language teaching program. it allows teachers and stakeholders, including program administrators, parents, admissions officers and prospective employers to be assured that the learners are progressing according to an accepted standard (douglas, 2010). the problems currently facing language testers have both practical and theoretical implications but the first i...
Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer
TO THE EDITOR: I have concerns about the reported results in the recent apatinib trial by Li et al in Chinese patients with gastric cancer. In superiority trials, intention-to-treat (ITT) analyses that include all patients according to the allocated treatment are standard. This can lead to a conservative estimate of effect size and avoid bias associated with nonrandom loss of participants; howe...
متن کاملEfficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
OBJECTIVE No standard chemotherapy is available for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed prior first-line chemotherapy. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR-2 inhibitor, as salvage treatment for advanced ESCC. PATIENTS AND METHODS After apatinib dosing, the efficacy and toxicity were evaluated in 6...
متن کاملApatinib in Advanced Gastric Cancer: A Doubtful Step Forward
TO THE EDITOR: Li et al have recently reported the results of a phase III trial that evaluated apatinib treatment in patients with advanced gastric cancer who experienced disease progression after two or more lines of systemic therapy. The authors compared apatinib—a tyrosine kinase inhibitor that targets the vascular endothelial growth factor receptor-2 (VEGFR-2)—with placebo among 273 randoml...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.1526